Loading...
•
Dec 31, 2024
Entrada Therapeutics Q4 2024 Earnings Report
Entrada Therapeutics' Q4 2024 financial results were reported, highlighted by FDA authorization to initiate ELEVATE-44-102 in the U.S. and MHRA authorization to initiate ELEVATE-44-201 in the U.K.
Key Takeaways
Entrada Therapeutics reported a net income of $1.1 million for Q4 2024, with collaboration revenue reaching $37.4 million. The company's cash, cash equivalents, and marketable securities totaled $420 million, expected to fund operations into Q2 2027.
Received FDA authorization to initiate ELEVATE-44-102 in the U.S.
Received MHRA authorization to initiate ELEVATE-44-201 in the U.K.
Submitted regulatory filings to support global clinical studies for ENTR-601-44 in the EU, and ENTR-601-45 in the U.K. and EU.
Cash runway expected into Q2 2027 with $420 million in cash, cash equivalents and marketable securities as of December 31, 2024.
Entrada Therapeutics
Entrada Therapeutics
Entrada Therapeutics Revenue by Segment
Revenue by Segment
Collaboration Revenue
CapyFin.com Forward Guidance
Entrada Therapeutics anticipates continued progress in its clinical programs and expects its current cash resources to be sufficient to fund operations into the second quarter of 2027.
Positive Outlook
- Advancing Duchenne muscular dystrophy franchise.
- Potential best-in-class therapy to patients and their families.
- Positive data has supported regulatory clearance in multiple geographies for ELEVATE-44 program.
- Accelerated pace at which programs are advancing.
- People, pipeline and resources to deliver on mission for patients and investors.
Challenges Ahead
- Uncertainties inherent in the identification and development of product candidates.
- Uncertainties as to the availability and timing of results from preclinical and clinical studies.
- The timing of and Entrada’s ability to submit and obtain regulatory clearance and initiate clinical studies.
- Whether results from preclinical studies or clinical studies will be predictive of the results of later preclinical studies and clinical studies.
- Whether Entrada’s cash resources will be sufficient to fund the Company’s foreseeable and unforeseeable operating expenses and capital expenditure requirements.